Sialomucin and lytic susceptibility of rat mammary tumor ascites cells.
The potential role of cell surface sialomucin in preventing natural killer (NK)-mediated lysis of tumor cell targets has been addressed by comparing the properties of 2 NK-resistant [ascites (ASC) and short-term cultured (STC)] and 2 NK-susceptible [tunicamycin-treated (TUN) and long-term cultured (LTC)] preparations of 13762 MAT-B1 rat mammary tumor cells. Both the ASC and STC cell preparations contain elevated levels of the sialomucin ASGP-1 relative to TUN and LTC preparations as determined by [3H]glucosamine labeling and by binding of peanut agglutinin. The major difference in the susceptibility to NK-mediated lysis appeared to be due to the differences in the susceptibility to lysis by lytic granules, rather than to differences in the ability to bind or trigger effector cells, since TUN and LTC cells were approximately 10-fold more sensitive to lysis by lytic granules than were ASC and STC cells. All preparations inhibited the lysis of the susceptible target YAC-1 by normal rat splenocytes, indicating an ability to bind these effector cells. Triggering of effectors, as monitored either by incorporation of 32P into phosphatidylinositol or by transmethylation of phosphatidylcholine, was similar for the positive control YAC-1, STC, TUN, and LTC, whereas ASC appeared to be defective in triggering effectors. These results suggest that tumor sialomucin blocks the final phase of lysis, but not the initial recognition of tumor cells by NK effectors.
Moriarty
J
J
Department of Biochemistry University of Maine, Orono 04469.
Skelly
C M
CM
Bharathan
S
S
Moody
C E
CE
Sherblom
A P
AP
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001201:Ascites / Q000378:metabolism / Q000473:pathology; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D007694:Killer Cells, Natural / Q000502:physiology*; D050356:Lipid Metabolism; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism* / Q000473:pathology; D009077:Mucins / Q000378:metabolism* / Q000502:physiology; D051381:Rats; D052116:Sialomucins; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014415:Tunicamycin / Q000494:pharmacology
D006023:Glycoproteins; D009077:Mucins; D052116:Sialomucins; D014409:Tumor Necrosis Factor-alpha; D014415:Tunicamycin